The letter, published on 24 August 2026 as volume 22, article 145 of the journal, is framed as a response to a randomized crossover trial by Deflorin and colleagues that examined the effect of short-term descent to low altitude in healthy residents living at moderate altitude. That trial addressed a genuinely important question: whether periodic dips into lowland conditions can reset the respiratory disturbances that accumulate during chronic residence at elevation. The letter writers do not dispute the physiological value of such work. Instead, they argue that the interpretation of altitude-related sleep-disordered breathing has been too narrowly physiological, and that a behavioral perspective can explain why identical hypoxic exposures produce wildly different clinical outcomes in different people.

The technical core of the physiological account is well established. As barometric pressure falls with altitude, the partial pressure of inspired oxygen drops, arterial oxygen saturation declines, and the peripheral chemoreceptors in the carotid bodies respond by driving ventilation upward. This increased ventilation washes out carbon dioxide, and because carbon dioxide is the primary stimulus for the central respiratory controller during sleep, the system can overshoot into hypocapnia. Below a critical threshold of carbon dioxide tension, the brainstem temporarily halts the drive to breathe, producing central apneas. Oxygen desaturation then reactivates the chemoreflex, ventilation surges again, and the cycle repeats in the stereotyped waxing-and-waning pattern of periodic breathing. This loop explains why even healthy, non-snoring mountaineers can experience apnea indices at altitude that would satisfy diagnostic criteria for sleep apnea at sea level.

What the physiological model struggles to explain, the authors argue, is variability. Not everyone at the same altitude develops the same severity of sleep-disordered breathing, and not everyone who does develops the symptoms, distress, or functional impairment that the objective measurements might predict. The letter points toward a growing literature showing that how people perceive their sleep, how they interpret their symptoms, and whether they seek help are powerful modifiers of clinical reality. A cited study by Duarte and colleagues on adults with suspected obstructive sleep apnea found that perceptions of sleep duration frequently diverge from objectively measured sleep, a mismatch that can distort both diagnosis and the perceived need for treatment. If perception can decouple from measurement in ordinary clinic populations, the authors reason, it can do so even more dramatically in the unusual and poorly understood context of altitude.

The behavioral argument also draws on qualitative research into help-seeking. A 2026 study by Bhaskaran and colleagues of undergraduate medical students explored perceived risk, symptoms, and help-seeking behavior for obstructive sleep apnea, and found that even among people with medical training, recognition of sleep-disordered breathing as a condition warranting evaluation was far from automatic. Stigma, minimization of snoring and witnessed apneas, and simple unfamiliarity with the disorder all delayed presentation. Translated to altitude settings, this suggests that residents of mountainous regions, migrants to high-elevation cities, and even transient visitors such as trekkers and workers may systematically under-recognize or misattribute their nocturnal breathing disturbances, chalking them up to strange beds, cold air, travel fatigue, or stress rather than to a measurable and manageable physiological phenomenon.

Adherence adds a second behavioral layer. The letter cites the classic qualitative work of Sawyer and colleagues, who documented profound differences in how adherent and non-adherent patients perceived their obstructive sleep apnea diagnosis and continuous positive airway pressure therapy. Non-adherers described masks as uncomfortable, benefits as intangible, and the diagnosis itself as ambiguous, while adherers reported noticeable daytime improvement that reinforced continued use. The implication for altitude medicine is direct: interventions for altitude-related sleep-disordered breathing, whether oxygen supplementation, medications such as acetazolamide, or descent itself, succeed or fail partly on behavioral grounds. A therapy that is physiologically elegant but behaviorally unacceptable will not be used, and an interpretation of the disorder that ignores this fact will mispredict outcomes.

The letter’s authors, who span five Indonesian universities including Universitas Sebelas Maret, Universitas Islam Balitar, Universitas Kanjuruhan Malang, and Universitas Negeri Surabaya, bring a perspective shaped by a country whose territory includes both densely populated lowlands and significant highland communities. Indonesia’s highland populations, along with the millions of people worldwide who live above 1,500 meters in the Andes, the Himalayas, the Ethiopian Highlands, and the mountainous American West, represent a substantial global population for whom altitude-related sleep disturbances are a nightly reality rather than an expedition curiosity. For these communities, the question of whether periodic breathing is a benign acclimatization phenomenon or a clinically meaningful disorder is not academic; it shapes whether people seek care, whether physicians look for it, and whether health systems allocate resources to it.

The behavioral perspective also reframes the interpretation of research findings such as the Deflorin descent trial. If short-term descent improves sleep-disordered breathing in moderate-altitude residents, the clinical significance of that improvement depends on what residents actually experience and do. Someone who perceives their altitude sleep as restorative may report better daytime function regardless of modest changes in apnea-hypopnea indices, while someone who has learned to fear their fragmented sleep may experience persistent insomnia symptoms even after objective respiratory parameters normalize. Perception, expectation, and coping behavior can amplify or dampen the functional consequences of the same physiological signal, which means that trials measuring only respiratory variables may systematically underestimate or mischaracterize the benefits of interventions.

There is also a diagnostic dimension to the argument. Standard sleep apnea criteria were developed and validated at or near sea level, and applying them uncritically at altitude risks pathologizing adaptive responses such as periodic breathing that may carry little long-term harm in otherwise healthy residents. Conversely, a purely physiological interpretation risks missing the minority of altitude dwellers whose sleep-disordered breathing is compounded by anatomical obstruction, obesity, or overt heart failure, and who would benefit most from intervention. Behavioral information, including symptom perception, functional impact, and help-seeking readiness, can help clinicians distinguish adaptive periodic breathing from clinically significant disease in ways that oximetry traces alone cannot.

The letter, whose authors report no funding and no competing interests, does not present new experimental data; no datasets were generated or analyzed in its preparation. Its contribution is conceptual, urging the sleep medicine community to widen its interpretive frame. In an era when portable sleep monitoring makes it feasible to study breathing in remote highland homes rather than laboratories, the authors suggest that future studies should pair physiological measurements with validated assessments of sleep perception, symptom attribution, and treatment attitudes. Such integrated designs could finally explain why two people with identical desaturation profiles at the same altitude can inhabit utterly different clinical worlds, one sleeping soundly through periodic breathing and the other suffering through every fragmented night. The message is a humbling one for a field built on chemoreflex loops and pressure gradients: the air explains the apnea, but human behavior explains the disease.

Subject of Research: Behavioral influences on sleep-disordered breathing at high altitude

Article Title: Broadening the interpretation of altitude-related sleep-disordered breathing: a behavioral perspective

Article References: Broadening the interpretation of altitude-related sleep-disordered breathing: a behavioral perspective. (n.d.). https://doi.org/10.1007/s44470-026-00172-x

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00172-x

Keywords: sleep-disordered breathing, high altitude, periodic breathing, obstructive sleep apnea, hypoxia, sleep perception, CPAP adherence, help-seeking behavior, altitude medicine, respiratory physiology, Journal of Clinical Sleep Medicine, behavioral health

The technical problem at the heart of the debate concerns the hypopnea, defined as a partial reduction in airflow during sleep, in contrast to a complete apnea. Standard polysomnography records airflow through nasal pressure cannulas and thermal sensors, alongside respiratory effort belts and oximetry that tracks blood oxygen. Obstructive events are those in which effort continues while the airway collapses; central events are those in which the brain simply stops issuing the neural commands to breathe. Hypopneas, because they are partial, sit awkwardly in this binary scheme. A shallow breath can arise from a partly closed airway, from a weak central drive, or from a combination of the two, and the signal differences on a routine recording can be subtle enough that scorers disagree.

This ambiguity matters because the two categories point to different physiology and, potentially, different treatments. Obstructive events respond to continuous positive airway pressure, oral appliances, and airway-focused interventions. Central events, which reflect instability in the feedback loop that controls ventilation, may respond poorly or even paradoxically to standard pressure therapy, and are managed with different tools entirely, from adaptive servo-ventilation to medications that adjust chemosensitivity. If a hypopnea that is truly central in origin is counted as obstructive, a patient may receive a diagnosis whose treatment pathway is mismatched with the underlying mechanism.

The letter builds on a recent position paper in the same journal in which Ahn, Azarbarzin, Badr, Berry, and colleagues argued that classifying central hypopneas is important enough to warrant coordinated action by the sleep medicine community. Kumari’s contribution extends that argument by asking a more fundamental question: what is the point of identifying an event if knowing its type does not change what happens to the patient next? Drawing on a framework for evaluating diagnostic tests developed by di Ruffano, Hyde, McCaffery, Bossuyt, and Deeks in the British Medical Journal, she frames central hypopnea classification not as a scoring exercise but as a test whose value must be demonstrated in a chain that runs from detection, to differential diagnosis, to treatment selection, to measurable improvement in health.

That framework, originally developed to help researchers design trials of diagnostic technologies, imposes a discipline that sleep scoring has largely escaped. A diagnostic test earns its place in clinical practice by showing that its results lead to better decisions and better outcomes, not merely that it produces numbers. Applied to hypopnea classification, the question becomes whether knowing that a given hypopnea is central rather than obstructive actually alters management in ways that benefit the patient. The letter suggests that the field cannot answer this question with confidence, because the necessary evidence linking event phenotype to treatment response has never been systematically assembled.

The second pillar of the argument comes from a consensus statement led by Malhotra, Ayappa, Ayas, Collop, Kirsch, and McArdle, published in the journal Sleep, on metrics of sleep apnea severity beyond the apnea-hypopnea index. That statement catalogued the shortcomings of the AHI, the single number that has dominated sleep medicine since its inception. The AHI counts all apneas and hypopneas per hour of sleep regardless of type, position, or physiological consequence. Two patients with identical AHI values can carry very different burdens of disease: one may have long, severely desaturating events concentrated in REM sleep, while the other has short, benign events scattered across the night. Collapsing this heterogeneity into one figure discards exactly the information that might guide treatment.

Central hypopneas sit at the sharp edge of this metric problem. Because scoring rules allow hypopneas to be identified through airflow reduction with or without associated desaturation or arousal, depending on the rule set in use, the same recording can yield different AHI values under different guidelines. When central events are lumped together with obstructive ones, the resulting index reflects neither the mechanical burden of airway collapse nor the control-system instability of central apnea. For conditions in which central events predominate, such as heart failure-associated central sleep apnea or opioid-induced respiratory depression, an AHI that blends event types may actively mislead the clinician about both severity and prognosis.

The physiological stakes are considerable. Central respiratory events arise from instability in the loop gain of the ventilatory control system, the sensitivity with which the brain responds to fluctuations in carbon dioxide and oxygen. High loop gain produces overshoot and undershoot in ventilation, creating cyclical patterns such as Cheyne-Stokes breathing. This instability is not a mechanical problem that a splinted airway can fix; it is a control problem with its own pharmacology and its own device solutions. Identifying central hypopneas is therefore a step toward measuring loop gain and control instability in ordinary clinical recordings, which could eventually allow clinicians to select patients for servo-ventilation or other control-targeted therapies on a rational basis rather than by trial and error.

The letter also highlights the human cost of the status quo. Patients whose symptomatic breathing disturbances are scored as mild or equivocal may be denied insurance coverage for therapy, told their sleep study was normal, or left to cycle through ineffective treatments. Conversely, patients whose events are counted but whose event type is misclassified may undergo positive airway pressure trials that fail, reinforcing a cycle of non-adherence and clinical frustration. Kumari argues that rigorous, clinically validated classification of central hypopneas would sharpen the diagnostic pathway at both ends, directing the right patients to the right interventions and sparing others inappropriate treatment.

The path forward, as the letter sketches it, follows the logic of the diagnostic-test framework: define the clinical decision the classification is meant to inform, gather evidence that the distinction changes that decision, and then test whether patients whose management is guided by event type fare better than those managed on AHI alone. That program requires agreement on scoring criteria for central hypopneas, prospectively collected data linking event phenotype to treatment response, and trial designs that treat classification as an intervention in its own right. None of this is easy, and the letter does not pretend otherwise. Its central claim is simpler and harder to dismiss: a measurement that has never been shown to change a clinical decision is a measurement awaiting justification, and for central hypopneas the justification has not yet been built. As sleep medicine moves toward richer phenotyping of sleep-disordered breathing, closing the gap between event identification and clinical utility has become the test that the field’s most familiar number must finally pass.

Subject of Research: Clinical classification of central hypopneas in sleep-disordered breathing diagnosis and the validation of diagnostic utility

Article Title: Central hypopnea classification: bridging the gap between event identification and clinical utility

Article References: Kumari, N. (2026). Central hypopnea classification: bridging the gap between event identification and clinical utility. Journal of Clinical Sleep Medicine, 22(1), Article 172. https://doi.org/10.1007/s44470-026-00202-8

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00202-8

Keywords: central hypopnea, sleep apnea, polysomnography, apnea-hypopnea index, sleep medicine, respiratory events, diagnostic testing, loop gain, positive airway pressure, sleep-disordered breathing, Journal of Clinical Sleep Medicine, Central

The letter, written by Anmol Devi of Ghulam Muhammad Mahar Medical College in Sukkur, Pakistan, examines a recent study by Murray and colleagues that evaluated a photoplethysmography-based home sleep apnea test, known as PPG-HSAT, against polysomnography in children aged two to six years. Polysomnography, or PSG, remains the gold standard for diagnosing obstructive sleep apnea in children, but it is expensive, resource-intensive, and often uncomfortable for young patients. A reliable home alternative would be transformative, allowing clinicians to screen and diagnose far more children in their own sleep environments. The appeal is obvious, which is precisely why Devi argues that the methodological details behind accuracy claims deserve close scrutiny.

The first concern centers on what happens when the home test simply fails to produce usable data. In the original study, 43 children attempted concurrent testing with both the home device and laboratory polysomnography. Four of them, roughly nine percent, had no interpretable PPG-HSAT data at all. Among the 39 children with some captured data, a further 11, or 28 percent, had less than two hours of recorded sleep. Despite these substantial losses, the study calculated sensitivity, specificity, positive predictive value, and negative predictive value only among the children whose home recordings were successfully captured. The headline figures were striking: a sensitivity of 94.1 percent, meaning the device caught nearly all true cases, but a specificity of just 22.7 percent, meaning it flagged many children as positive who did not have the condition by the reference standard.

Devi’s argument is that these numbers may not mean what they appear to mean. In diagnostic accuracy research, excluding missing or inconclusive index-test results is a well-recognized source of bias. When only technically successful recordings are analyzed, the study population becomes a selected subset, potentially healthier in terms of device tolerance or simply easier to monitor, and therefore less representative of the intended clinical population. A device that fails in a quarter of attempted recordings is not the same device, in clinical terms, as one evaluated only where it worked. The reported sensitivity and specificity may reflect performance among technically successful recordings rather than the overall diagnostic effectiveness of the test as it would be deployed in practice.

The solution Devi proposes draws on established methodological literature. An intention-to-diagnose analysis, analogous in spirit to intention-to-treat analysis in therapeutic trials, would classify technically unsuccessful studies as indeterminate or failed tests rather than discarding them. This approach, supported by a scoping review of methods for handling missing values and inconclusive results in diagnostic studies published in Statistical Methods in Medical Research, yields estimates that better reflect real-world performance. It answers the question clinicians actually face: if I prescribe this home test for a toddler suspected of having sleep apnea, how likely am I to get an accurate answer, or any answer at all? A test with excellent accuracy conditional on success but a high failure rate may be far less useful than its published numbers suggest.

The second methodological concern involves the reference standard itself. Polysomnography is only as unbiased as the people interpreting it, and Devi notes that in the original study, PSG technologists and physicians were not blinded to study participation. Moreover, the PSG interpretation incorporated audiovisual findings, including snoring, mouth breathing, and airway-protective maneuvers. These observations are clinically valuable, but they also carry subjective judgment, and their integration into the diagnostic classification opens the door to what the literature calls diagnostic review bias, which arises when interpreters of the reference standard are aware of the index-test result or the investigational context.

The letter acknowledges that the original authors reported the SleepImage data, the commercial PPG-based system under evaluation, were reviewed independently at a later time. That is an important safeguard for the index test. What remains unclear, Devi writes, is whether the PSG interpretation was fully independent of the investigational testing context. If the sleep technologists scoring the reference standard knew that a child was part of a study evaluating a home apnea test, even subtle expectations could color their reading of borderline respiratory events. This may be particularly consequential in pediatric obstructive sleep apnea, where classification often hinges on borderline cases and where clinical and audiovisual findings, such as a parent’s report of snoring or visible mouth breathing, can influence whether a child crosses the diagnostic threshold.

Diagnostic review bias is not a hypothetical worry. Reviews of diagnostic accuracy methodology, including work published in Radiology Research and Practice on recognizing and addressing sources of bias, have repeatedly shown that unblinded reference-standard interpretation can inflate apparent agreement between tests and distort estimates of sensitivity and specificity. In fields like radiology, where imaging studies are routinely compared against clinical reference standards, blinding procedures are now considered a core quality marker of accuracy research. Sleep medicine, Devi implies, should hold itself to the same standard, especially as commercial home-testing platforms seek regulatory approval and clinical adoption on the basis of validation studies.

Importantly, the letter does not claim that the original study’s findings are invalid. Devi explicitly states that these issues do not invalidate the study, but that they may affect the reported estimates of diagnostic performance. The distinction matters. The Murray study addresses an important clinical question, and the underlying data remain valuable. The concern is about interpretation: how far the reported sensitivity of 94.1 percent and specificity of 22.7 percent can be generalized to the population of children who would actually be offered the test, including those whose recordings fail or fall short of adequate sleep duration.

The broader stakes extend well beyond a single study. Pediatric obstructive sleep apnea affects a meaningful share of preschool children and is associated with behavioral problems, poor growth, cardiovascular strain, and impaired quality of life. Untreated, it can shape a child’s development during critical years. Yet access to polysomnography is limited in many regions, and waiting lists for pediatric sleep laboratories can stretch for months. If home sleep apnea tests can be validated rigorously for young children, the public health payoff could be enormous: earlier diagnosis, earlier treatment with adenotonsillectomy or other interventions, and reduced burden on families. That promise is exactly why methodological rigor in validation studies is not an academic nicety but a prerequisite for safe clinical adoption.

Devi’s recommendations are concrete. Future evaluations of pediatric home sleep apnea tests should account for technically unsuccessful recordings, reporting them transparently and incorporating them into intention-to-diagnose analyses, and should ensure independent, ideally blinded, interpretation of the reference standard. Such measures would provide more robust and clinically meaningful estimates of accuracy, allowing clinicians and regulators to judge these devices on the terms that matter: how they perform in the full population of children who would use them, not just the subset in whom they happen to work. As home testing moves from novelty toward standard of care, the letter serves as a timely reminder that in diagnostic medicine, the fine print of methodology often determines whether a promising technology earns its place at the bedside, or in this case, the child’s own bedroom.

Subject of Research: Methodological biases in validating home sleep apnea tests against polysomnography in preschool children

Article Title: Methodological considerations in assessing diagnostic accuracy of home sleep apnea tests in children

Article References: Devi, A. (2026). Methodological considerations in assessing diagnostic accuracy of home sleep apnea tests in children. Journal of Clinical Sleep Medicine, 22(1), Article 159. https://doi.org/10.1007/s44470-026-00185-6

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00185-6

Keywords: home sleep apnea test, pediatric sleep apnea, polysomnography, photoplethysmography, diagnostic accuracy, intention-to-diagnose analysis, diagnostic review bias, PPG-HSAT, children aged 2 to 6, sleep medicine, reference standard blinding, Journal of Clinical Sleep Medicine

The letter, written by Nashmia Faraz, Haider Imran and Abdul Basit of the Department of Medicine at Foundation University Medical College in Islamabad, Pakistan, takes aim at the gap between objective and subjective measures of adherence in oral appliance therapy. Published in September 2026, the correspondence responds to emerging longitudinal evidence on how adults with obstructive sleep apnea actually use their appliances over a full year, and it argues that the field must refine how adherence is defined, measured and interpreted before the therapy’s real-world effectiveness can be judged fairly.

The concern is not academic hair-splitting. An oral appliance that sits in a drawer delivers no therapeutic benefit, no matter how well it was designed or how effectively it advanced the jaw in a laboratory titration study. Adherence is the hinge on which the entire treatment turns. For CPAP, this lesson was learned early and painfully: studies famously showed that early patterns of use in the first days and weeks strongly predicted long-term adherence, prompting sleep medicine to invest heavily in objective compliance monitoring, telehealth coaching and early intervention programs. Modern CPAP machines log every hour of use, and those data streams are now woven into routine care. Oral appliance therapy, by contrast, has largely depended on what patients report at follow-up visits.

Self-report is a notoriously fragile foundation for clinical decisions. Patients may genuinely believe they wear their devices more than they do, because nights of fragmented sleep blur memory and because social desirability nudges people toward the answers they think their clinicians want to hear. The literature cited in the letter makes the scale of the discrepancy unmistakable. A landmark 2013 study published in Chest by Dieltjens and colleagues compared objectively measured compliance, captured by embedded microsensors, with self-reported compliance among patients using mandibular advancement devices for sleep-disordered breathing. The objective data revealed substantially lower usage than patients reported, exposing a gap large enough to distort outcome studies, cost-effectiveness analyses and clinical audit alike.

Embedded microsensors have since become the technical benchmark for objective adherence measurement in oral appliance therapy. These tiny temperature-sensitive chips sit inside the appliance and register when the device is actually in the mouth, distinguishing genuine use from mere possession. When the appliance is inserted, oral temperature triggers the sensor; when it rests on a bedside table, no temperature change is recorded. The approach mirrors the objective compliance chips that transformed CPAP monitoring, and it offers sleep medicine something it has long lacked for dental devices: a truthful, time-stamped record of real-world use patterns, including how many nights per week the appliance is worn and for how many hours per night.

The new longitudinal pilot data that prompted the letter tracked both objective and subjective adherence in adults with obstructive sleep apnea over one year, providing a rare window into how usage evolves well beyond the initial adaptation period. The corresponding letter argues that such data should push the field toward a more nuanced adherence framework, one that distinguishes between objective device use, patient-perceived use and clinical response, rather than collapsing them into a single self-reported figure. The authors, who conceptualized and drafted the correspondence with no external funding and no competing interests, position their contribution as a call to tighten the methodological standards of oral appliance research.

Why does this refinement matter now? Oral appliance therapy is expanding rapidly. Clinical guidelines recommend it for patients with mild to moderate obstructive sleep apnea and for those with severe disease who cannot tolerate or decline CPAP. Dental sleep medicine has grown into a distinct subspecialty, and the global market for mandibular advancement devices continues to climb as obesity rates and disease prevalence rise. Every prescription implicitly assumes that the device will be worn consistently. If adherence measurement lags behind prescription volume, the field risks both overtreatment, with devices dispensed to patients who will never use them, and undertreatment, with genuine adherence problems overlooked until symptoms return or cardiovascular risk quietly accumulates.

The letter also draws an instructive parallel with the CPAP literature, including the 2007 study by Budhiraja and colleagues in the journal Sleep demonstrating that early CPAP use identified subsequent long-term adherence. That finding reshaped clinical practice, motivating early follow-up and, eventually, remote monitoring programs that flag struggling patients within days. For oral appliances, the analogous evidence base is younger and thinner, but studies such as the 2022 investigation by Kwon and colleagues in the Journal of Sleep Research show that remote monitoring and structured feedback can measurably improve objective compliance with mandibular advancement devices. Together, these strands of evidence suggest that objective adherence measurement is not merely a research nicety; it is the enabling technology for the same kind of proactive, data-driven care that rescued CPAP adherence a generation ago.

The technical challenges, however, are real. Microsensor data must be validated against true wear events, sensors can fail or be damaged during cleaning, and different sensor generations may not produce comparable metrics. The field lacks universally accepted adherence thresholds for oral appliances, whereas CPAP benefited from widely used conventions such as the Medicare definition of four hours per night on seventy percent of nights, itself a contested standard. Without consensus definitions, meta-analyses of appliance effectiveness will continue to mix studies whose adherence figures mean different things, blurring genuine differences in therapeutic efficacy with differences in measurement practice. The authors of the letter imply that resolving this definitional tangle is a prerequisite for the next generation of oral appliance research.

What would refined adherence assessment look like in practice? The ingredients are already on the table: objective sensor-derived metrics reporting nights and hours of use, patient-reported measures captured with validated questionnaires, and clinical outcomes such as the apnea-hypopnea index on follow-up polysomnography or home testing. Longitudinal designs, like the one-year pilot study that sparked the correspondence, add the crucial temporal dimension, revealing whether adherence decays over months and which patients are at greatest risk of abandoning therapy. Integrating these data streams into electronic health records and telemedicine platforms could finally give dental sleep medicine the feedback loops that clinicians need, allowing early, targeted interventions before non-adherence becomes entrenched. As oral appliance therapy takes its place alongside CPAP in mainstream sleep medicine, the message from Islamabad is clear: the therapy can only be as good as the evidence that patients are actually using it, and measuring that use honestly is the field’s next essential task.

Subject of Research: Objective versus subjective adherence assessment in oral appliance therapy for obstructive sleep apnea

Article Title: Refining adherence assessment in oral appliance therapy for obstructive sleep apnea

Article References: Faraz, N., Imran, H., & Basit, A. (2026). Refining adherence assessment in oral appliance therapy for obstructive sleep apnea. Journal of Clinical Sleep Medicine, 22(1), Article 158. https://doi.org/10.1007/s44470-026-00176-7

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00176-7

Keywords: obstructive sleep apnea, oral appliance therapy, mandibular advancement device, adherence measurement, microsensors, CPAP, sleep medicine, self-reported compliance, remote monitoring, dental sleep medicine, Journal of Clinical Sleep Medicine, Refining

The letter is a critical appraisal of a real-world study by Ahn and colleagues that examined whether GLP-1RAs act as cardiovascular risk modifiers in people with obstructive sleep apnea and obesity. Real-world studies of this kind have become enormously influential because they mine large clinical databases to answer questions that randomized trials either have not yet addressed or cannot practically address. With millions of patients now prescribed GLP-1RAs for type 2 diabetes, obesity, and increasingly for their demonstrated cardiovascular benefits, the stakes for getting these observational analyses right could hardly be higher. Policy decisions, prescribing patterns, and reimbursement frameworks increasingly rest on the kind of database evidence that Sarıoğlu’s letter scrutinizes.

At the heart of the critique lies a technical concept that has shaped pharmaco-epidemiology for nearly two decades. Immortal time bias arises when a period of time during which the outcome of interest cannot occur is improperly included in one group’s follow-up, typically the treated group. The classic formulation comes from epidemiologist Samy Suissa, whose 2008 paper in the American Journal of Epidemiology laid out how this bias operates: if researchers define the exposed group by a prescription that occurs sometime after cohort entry, but count that patient’s follow-up from the moment of entry, the patient must survive long enough to receive the prescription. That guaranteed survival window, the ‘immortal time,’ makes the treated group appear artificially protected, generating spuriously favorable results for the drug.

Sarıoğlu points out that this structure is particularly easy to fall into when studying GLP-1RAs, because these drugs are often initiated months or even years after a patient first enters the health system with obesity, sleep apnea, or diabetes. When investigators anchor their analysis at the date of an obstructive sleep apnea diagnosis or at a baseline clinic visit, but classify patients as GLP-1RA users only once a prescription appears later in their record, the exposed group has, by construction, accumulated event-free time before treatment ever began. Unless the analysis explicitly accounts for that window—through techniques such as time-dependent exposure modeling, matching on the time to treatment, or active-comparator new-user designs—the resulting hazard ratios can suggest cardiovascular protection that reflects study design rather than pharmacology.

The letter also situates its argument within a broader and ongoing refinement of how epidemiologists understand these biases. A 2025 paper by Miguel Hernán and colleagues in the journal Epidemiology provided a structural description of the family of biases that generate immortal time, framing them through the lens of causal diagrams and target trial emulation. That work emphasized that immortal time bias is not a single mistake but a constellation of design choices—how cohorts are defined, how exposure is classified, how follow-up begins and ends—that collectively manufacture a comparison between people who could not yet have experienced an event and those who could. Sarıoğlu’s letter applies this modern framework to the specific case of GLP-1RAs in sleep apnea populations, effectively asking whether the original study emulated the randomized trial it intended to mimic.

The target trial framework, as it is known, asks investigators to specify, before touching the data, the randomized trial they would ideally conduct: who would be eligible, how treatment would be assigned, when follow-up would start, and what outcome would be measured. In a well-executed emulation, the moment of cohort entry and the moment treatment is assigned coincide, or the analysis explicitly handles the gap between them. When they diverge—as they do whenever a prescription recorded at an arbitrary later date defines the exposed group—the emulation drifts away from the trial it was meant to mirror, and the divergence is precisely where bias enters. Sarıoğlu’s central claim is that the timing of exposure classification in real-world cardiovascular analyses of GLP-1RAs represents exactly such a divergence, and that readers should interpret effect estimates from such studies with corresponding caution.

Why does this matter so much for this particular drug class and this particular patient population? Obstructive sleep apnea affects roughly a billion people worldwide and is strongly associated with obesity, hypertension, arrhythmias, and increased cardiovascular mortality. GLP-1RAs have generated intense excitement because randomized trials in other populations, notably patients with type 2 diabetes and established cardiovascular disease, showed meaningful reductions in major adverse cardiovascular events. Translating those findings to sleep apnea populations through observational data is an attractive and legitimate research strategy. But it is also a strategy in which the exposure is highly patterned by the very health trajectories under study: patients who remain well enough, engaged enough with care, and clinically stable enough to receive a GLP-1RA prescription are systematically different from those who deteriorate, drop out, or die before such a prescription is written. Any analysis that does not neutralize this selection can convert healthier-patient dynamics into apparent drug benefit.

The letter does not claim that GLP-1RAs lack cardiovascular benefits, nor does it assert that the original study’s conclusions are necessarily wrong. Its point is narrower and, in a sense, more important: the direction and magnitude of any bias introduced by exposure timing cannot be determined from the published results alone, and the credibility of real-world evidence for this drug class depends on design features that must be transparently reported. Sarıoğlu, writing as the sole author of the letter, conceived the commentary, reviewed the relevant literature, and drafted and revised the manuscript, drawing on no external funding and declaring no competing interests. The letter is based exclusively on critical appraisal of previously published work and involves no new data collection, which means its contribution is methodological rather than empirical—it is a lens, not a dataset.

The wider lesson extends well beyond sleep medicine. As GLP-1RAs are studied for an ever-expanding list of outcomes—from kidney disease and heart failure to dementia and addiction—real-world database studies will continue to proliferate, and each carries the same vulnerability if exposure timing is mishandled. The epidemiological community has developed reliable remedies: defining cohort entry at the moment of treatment eligibility, modeling exposure as a time-varying covariate, using new-user designs that exclude prevalent users, and emulating target trials with explicit cloning, censoring, and weighting strategies. Sarıoğlu’s letter serves as a reminder that applying these tools is not pedantic hair-splitting but the difference between evidence that can guide patient care and evidence that merely reflects who managed to stay alive and in care long enough to fill a prescription.

Published on 9 September 2026 as a letter to the editor in the Journal of Clinical Sleep Medicine, the commentary adds a careful methodological voice to one of the most consequential drug-evidence debates of the decade. Whether future real-world analyses of GLP-1RAs in obstructive sleep apnea and obesity will confirm, revise, or overturn the cardiovascular signals reported to date remains an open question. What the letter makes clear is that answering it responsibly requires paying close attention not just to whether patients took these drugs, but to precisely when the clock on their follow-up started—and whether that clock was fair to both the treated and the untreated.

Subject of Research: Methodological bias in real-world observational studies of GLP-1 receptor agonist exposure timing and cardiovascular risk in obstructive sleep apnea and obesity

Article Title: Timing of GLP-1RA exposure in real-world cardiovascular risk analyses

Article References: Sarıoğlu, G. (2026). Timing of GLP-1RA exposure in real-world cardiovascular risk analyses. Journal of Clinical Sleep Medicine, 22(1), Article 161. https://doi.org/10.1007/s44470-026-00188-3

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00188-3

Keywords: GLP-1 receptor agonists, immortal time bias, cardiovascular risk, obstructive sleep apnea, obesity, pharmaco-epidemiology, real-world evidence, observational studies, target trial emulation, type 2 diabetes, methodology, Journal of Clinical Sleep Medicine

At the center of the discussion is the MAGNETO study, a clinical investigation led by the Miami team that examined cognition and psychomotor vigilance in treated sleep apnea patients with and without daytime sleepiness. The study, published in the Journal of Clinical Sleep Medicine in 2026, addressed a puzzle that has troubled clinicians for decades: a substantial proportion of patients with obstructive sleep apnea who achieve excellent adherence to positive airway pressure, often measured as more than four hours of use per night on at least seventy percent of nights, nonetheless continue to report persistent daytime sleepiness. This residual sleepiness is not a trivial complaint. It is associated with impaired attention, slowed reaction times, reduced quality of life, and elevated risk for motor vehicle accidents and workplace errors.

The technical question underlying the exchange is deceptively simple: what causes sleepiness when the primary driver, repetitive upper airway collapse during sleep, has been mechanically corrected? Obstructive sleep apnea fragments sleep through hundreds of micro-arousals each night, triggers intermittent hypoxia and hypercapnia, and generates surges of sympathetic nervous system activity. Positive airway pressure splints the airway open, normalizes oxygen saturation, and dramatically reduces the arousal index. Yet objective sleepiness, as measured by the multiple sleep latency test, and subjective sleepiness, as captured by instruments such as the Epworth Sleepiness Scale, frequently persist. Estimates vary across cohorts, but studies have suggested that a meaningful fraction, often cited between six and fifteen percent of adherent patients, continue to experience clinically significant sleepiness despite normalized respiratory indices.

Riese and Koehler argued in their commentary that researchers and clinicians may be overlooking a mundane but powerful contributor: insufficient sleep opportunity during work weeks. Shift workers, long-haul drivers, physicians, and employees in demanding occupations routinely restrict their sleep to well below the recommended seven to nine hours, accumulating a chronic sleep debt that no airway device can repay. Their argument carries intuitive force, because laboratory studies of sleep restriction show that even healthy adults develop progressive deficits in vigilance and mood when sleep is curtailed night after night. A meta-analysis by Lim and Dinges, widely cited in the literature, demonstrated that short-term sleep deprivation reliably degrades attention and processing speed, with psychomotor vigilance tasks among the most sensitive measures of these deficits. In that sense, occupational sleep restriction is a plausible confounder in any study of sleepiness among employed apnea patients.

The Miami authors, however, contend that occupational factors cannot be treated as the single explanatory variable, and their reply emphasizes the multifactorial biology of residual sleepiness. Prior research has identified a constellation of mechanisms that operate independently of both apnea severity and sleep opportunity. These include subtle nocturnal hypoxemia that persists despite therapy, genetic polymorphisms affecting adenosine and monoamine signaling, obesity-related inflammatory pathways, and the phenomenon of phenotypic resistance in which certain individuals appear biologically less able to restore wakefulness even after mechanical correction of their breathing disorder. A study by Prasad and colleagues in the journal Sleep systematically examined determinants of sleepiness in obstructive sleep apnea and found that subjective and objective sleepiness have overlapping but distinct correlates, suggesting that different neural and metabolic pathways underlie each dimension.

Inflammation has emerged as a particularly compelling candidate mechanism. Work by Li, Vgontzas, and colleagues demonstrated that objectively sleepy apnea patients, but not subjectively sleepy ones, showed elevated circulating markers of inflammation such as interleukin-6 and tumor necrosis factor-alpha. This dissociation is scientifically important because it implies that objective sleepiness reflects a physiological state, potentially a chronic activation of immune signaling that alters sleep homeostatic pressure and wake-promoting circuits in the hypothalamus and brainstem. If inflammation drives a form of sleepiness that is independent of sleep duration, then simply asking patients about their work schedules would miss the relevant pathology entirely. The MAGNETO investigators argue that their findings on cognition and psychomotor vigilance fit within this broader model, in which residual sleepiness represents a genuine neurobiological phenotype rather than a simple arithmetic consequence of short sleep.

The Epworth Sleepiness Scale, developed by Murray Johns in 1991, remains the dominant clinical tool for quantifying subjective sleepiness, and it features prominently in this debate because of its well-known limitations. The scale asks patients to rate their likelihood of dozing in eight sedentary situations, but it conflates sleepiness with fatigue, boredom, and situational drowsiness, and it correlates only modestly with objective measures such as the maintenance of wakefulness test. Critics of sleepiness research, including Riese and Koehler, note that occupational demands can inflate Epworth scores without indicating any apnea-specific pathology. Defenders of the biological model counter that when objective measures of sleep propensity and cognitive performance, such as the psychomotor vigilance task used in the MAGNETO study, are added to the picture, the residual sleepiness phenotype remains robust and is not easily dismissed as an artifact of lifestyle.

From a clinical management standpoint, the stakes of this academic exchange are considerable. A growing pharmacological arsenal, including wake-promoting agents such as modafinil, armodafinil, and the dual orexin receptor antagonists solriamfetol, approved in 2019, and pitolisant, now offers targeted treatment for residual sleepiness in positive airway pressure-treated patients. The funding disclosure accompanying the Miami authors’ work notes support from Axsome Therapeutics and Jazz Pharmaceuticals, companies active in this therapeutic space, although the authors state that sponsors had no role in study design, data collection, analysis, or interpretation, and they declare no competing interests. If residual sleepiness is attributed primarily to occupational sleep restriction, the clinical response would be behavioral: extend sleep opportunity, adjust work schedules, and counsel patients on sleep hygiene. If instead it reflects a distinct biological susceptibility, then pharmacotherapy and further mechanistic research become the priority. The practical answer, most experts now agree, is likely a careful differential diagnosis that rules out inadequate sleep opportunity, depression, medications, and comorbid sleep disorders before attributing residual symptoms to an intrinsic sleepiness phenotype.

The broader significance of this debate extends well beyond the sleep clinic. Occupational health psychology has documented how constant connectivity and after-hours work erode psychological detachment from job demands, degrade sleep quality, and diminish morning vigor, findings described by Clinton and colleagues in the Journal of Occupational Health Psychology. In a workforce where chronic sleep insufficiency is endemic, distinguishing the sleepiness caused by a treated disease from the sleepiness caused by modern working life is an epidemiological challenge with implications for safety-critical industries, disability assessment, and drug development. The MAGNETO investigators argue that their data on cognition and vigilance in treated patients provide a rigorous framework for this differentiation, and their reply to Riese and Koehler underscores a central tenet of contemporary sleep science: residual excessive daytime sleepiness in positive airway pressure-adherent patients is best understood not as a single-cause problem but as a convergent phenotype, shaped by occupational sleep opportunity, inflammatory biology, genetic vulnerability, and the incomplete reversibility of chronic apnea-related neural injury. Resolving the relative weight of each factor will require larger, prospective studies that objectively measure both habitual sleep duration and the neurobiological markers of sleepiness, a research agenda both sides of this exchange could endorse.

Beyond the immediate exchange, the correspondence highlights a methodological point with consequences for future trials: standard adherence metrics capture device usage but say nothing about total sleep time. A patient may wear positive airway pressure for eight hours yet spend only five of them asleep, so respiratory indices can normalize while sleep debt persists undetected. Studies that simultaneously record actigraphy or polysomnography alongside PAP download data are better positioned to separate these contributions, and the Miami authors implicitly call for that level of measurement granularity.

The reply also illustrates how author correspondence functions within the specialty. Published as a formal response with its own digital object identifier, the letter allows the MAGNETO team to clarify scope and interpretation without altering the underlying study, while inviting the field to weigh the competing framings. Notably, the authors emphasized in their contribution statement that the reply was drafted and revised through internal review, with sponsors excluded from any role in its content.

For clinicians evaluating the sleepy but adherent patient, the exchange reinforces a layered diagnostic sequence: confirm adherence objectively, quantify sleep opportunity across work and rest days, screen for depression, medications, and comorbid disorders such as narcolepsy or periodic limb movement disorder, and consider objective testing when subjective reports conflict with performance measures. Only after these steps is it reasonable to invoke an intrinsic residual sleepiness phenotype. The dialogue between the two groups thus serves less as a verdict than as a roadmap, signaling that occupational context and neurobiology must be assessed together rather than pitted as rival explanations.

Subject of Research: Residual excessive daytime sleepiness in positive airway pressure-adherent obstructive sleep apnea patients

Article Title: Reply to “Occupational sleep restriction: a missing piece in residual EDS of PAP-adherent OSA?”

Article References: Junco, B., Ramos, A. R., & McIntosh, R. (2026). Reply to “Occupational sleep restriction: a missing piece in residual EDS of PAP-adherent OSA?”. Journal of Clinical Sleep Medicine, 22(1), Article 164. https://doi.org/10.1007/s44470-026-00173-w

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00173-w

Keywords: obstructive sleep apnea, excessive daytime sleepiness, positive airway pressure, occupational sleep restriction, MAGNETO study, Epworth Sleepiness Scale, psychomotor vigilance, sleep deprivation, inflammation, sleep medicine, cognition, Journal of Clinical Sleep Medicine